Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AbbVie Sets Out To Win Over Investors In Its First Financial Call

This article was originally published in The Pink Sheet Daily

Executive Summary

Management highlighted the ongoing growth potential of Humira and a late-stage pipeline that it says has the ability to generate between $4 billion and $6 billion of growth during the new pharmaceutical company’s first financial call with investors.

You may also be interested in...



Abbvie’s Elagolix Looks Set To Stake Claim In Endometriosis

Abbvie plans 2017 filing for elagolix, licensed from Neurocrine, after second Phase III trial leaves the oral drug with a competitive profile.

Gilles Picard On Steering AbbVie Across Asia, the Middle East And Africa: An Interview With PharmAsia News (Part 2 of 2)

Gilles Picard discusses how to reach patients across a mix of developed and frontier markets in his role as VP of Asia, Australia, Africa and the Middle East for AbbVie, the innovative biopharma company split from parent Abbott Laboratories at the start of the year.

Gilles Picard On Steering AbbVie Across Asia, the Middle East And Africa: An Interview With PharmAsia News (Part 1 of 2)

Gilles Picard discusses how to reach patients across a mix of developed and frontier markets in his role as VP of Asia, Australia, Africa and the Middle East for AbbVie, the innovative biopharma company split from parent Abbott Laboratories at the start of the year.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS074838

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel